Recombinant human parainfluenza virus type 2 vaccine candidates containing a 3′ genomic promoter mutation and L polymerase mutations are attenuated and protective in non-human primates

This publication has 46 references indexed in Scilit:

• Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates
  Vaccine, 2006
• Live-attenuated intranasal parainfluenza virus type 2 vaccine candidates developed by reverse genetics containing L polymerase protein mutations imported from heterologous paramyxoviruses
  Vaccine, 2005
• Identification of a Recombinant Live Attenuated Respiratory Syncytial Virus Vaccine Candidate That Is Highly Attenuated in Infants
  The Journal of Infectious Diseases, 2005
• Sendai Virus RNA-dependent RNA Polymerase L Protein Catalyzes Cap Methylation of Virus-specific mRNA
  Journal of Biological Chemistry, 2005
• Demystifying FluMist, a new intranasal, live influenza vaccine.
  Cleveland Clinic Journal of Medicine, 2003
• Chemical Mutagenesis of Dengue Virus Type 4 Yields Mutant Viruses Which Are Temperature Sensitive in Vero Cells or Human Liver Cells and Attenuated in Mice
  Journal of Virology, 2001
• Evaluation of a live attenuated bovine parainfluenza type 3 vaccine in two- to six-month-old infants
  The Pediatric Infectious Disease Journal, 1996
• Cold-passaged human parainfluenza type 3 viruses contain ts and non-ts mutations leading to attenuation in rhesus monkeys
  Virus Research, 1992
• The Role of Parainfluenza Viruses in Inspiratory Difficulties in Children
  Acta Paediatrica, 1988
• A Longitudinal Study of Respiratory Viruses and Bacteria in the Etiology of Acute Otitis Media with Effusion
  New England Journal of Medicine, 1982